JP4559531B1 - Method for producing nobiletin - Google Patents
Method for producing nobiletin Download PDFInfo
- Publication number
- JP4559531B1 JP4559531B1 JP2009275181A JP2009275181A JP4559531B1 JP 4559531 B1 JP4559531 B1 JP 4559531B1 JP 2009275181 A JP2009275181 A JP 2009275181A JP 2009275181 A JP2009275181 A JP 2009275181A JP 4559531 B1 JP4559531 B1 JP 4559531B1
- Authority
- JP
- Japan
- Prior art keywords
- nobiletin
- added
- formula
- solution
- och3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
【課題】ノビレチンおよびその誘導体の製造方法の提供。
【解決手段】β-ジケトン合成とそれに続くフラボン環化反応により、ノビレチンおよびその誘導体を合成する方法:
また、標識されたヨウ化メチルと反応させることにより、標識する方法。
【選択図】なしA method for producing nobiletin and its derivatives is provided.
A method for synthesizing nobiletin and its derivatives by β-diketone synthesis and subsequent flavone cyclization reaction:
A method of labeling by reacting with labeled methyl iodide.
[Selection figure] None
Description
本発明は、ノビレチンの新規合成方法および標識方法に関する。 The present invention relates to a novel synthesis method and labeling method of nobiletin.
ある種の柑橘類に含まれるノビレチンは、抗高血圧、抗癌作用などの多様な生理活性を示すことが報告されている(例えば、WO2006/049234)。また、アルツハイマー性記憶障害改善作用や抗認知症活性についても注目を集めている。ノビレチンは食品成分であり、服用における安全性が高いと考えられる。そのため、生理作用の機序が解明されれば、安全な医薬品としての応用が期待できる。 It has been reported that nobiletin contained in certain citrus fruits exhibits various physiological activities such as antihypertensive and anticancer effects (for example, WO2006 / 049234). In addition, attention has been focused on Alzheimer's memory impairment improving action and antidementia activity. Nobiletin is a food ingredient and is considered to be highly safe in taking. Therefore, if the mechanism of physiological action is elucidated, application as a safe pharmaceutical product can be expected.
しかしながら、現在試薬として入手可能なノビレチンは天然物から抽出したものであり、精製にコストがかかるため高価である。また、ノビレチンの各種の誘導体も得られていない。このため、構造活性相関の研究や、動物に及ぼす影響の研究はほとんど行われていない。 However, nobiletin currently available as a reagent is extracted from natural products and is expensive because of the cost of purification. In addition, various derivatives of nobiletin have not been obtained. For this reason, there has been little research on structure-activity relationships or effects on animals.
本発明は、ノビレチンおよびその誘導体の新規な合成方法、ならびにノビレチンおよびその誘導体の選択的標識方法を提供することを目的とする。 An object of the present invention is to provide a novel method for synthesizing nobiletin and its derivatives, and a method for selective labeling of nobiletin and its derivatives.
本発明は、式(I):
で表される化合物(ノビレチンまたはその5−OH誘導体)を合成する方法を提供する。この方法は、
(a)式(II):
で表される化合物とを反応させて、式(IV):
(b)式(IV)の化合物を環化させて、式(V):
(c)任意に、式(V)の化合物をAlCl3およびエタンチオールと反応させて、式(VI):
の各工程を含む。
The present invention is directed to formula (I):
A compound represented by the formula (nobiletin or a 5-OH derivative thereof) is synthesized. This method
(A) Formula (II):
Is reacted with a compound represented by formula (IV):
(B) cyclizing the compound of formula (IV) to form formula (V):
(C) Optionally reacting the compound of formula (V) with AlCl 3 and ethanethiol to give formula (VI):
Including each step.
別の観点においては、本発明は、式(VII):
で表される化合物を製造する方法を提供する。この方法は、式(V):
式(VI)の化合物を塩基の存在下で11Cまたは14Cで標識されたヨウ化メチルと反応させることにより、式(VII)の化合物を得る、
の各工程を含む。
In another aspect, the present invention provides a compound of formula (VII):
The method of manufacturing the compound represented by this is provided. This method uses the formula (V):
Reacting a compound of formula (VI) with methyl iodide labeled with 11 C or 14 C in the presence of a base to give a compound of formula (VII),
Including each step.
本発明の方法にしたがえば、ノビレチンおよびその種々の誘導体を容易かつ簡便に合成することができ、選択的に標識することができる。 According to the method of the present invention, nobiletin and its various derivatives can be synthesized easily and conveniently and can be selectively labeled.
本発明は、効率的なβ-ジケトン合成とそれに続くフラボン環化反応により、ノビレチン(1):
なお、本明細書の全体を通して、フラボン類の環および置換基の位置は次式:
本発明の方法の第1工程においては、フラボンA環部に相当するアセトフェノン誘導体(8)に対し、フラボンB環部に相当するジメトキシ安息香酸誘導体(9)(RはClまたはベンゾトリアゾリルである)を、THF 中 LHMDS(リチウムヘキサメチルジシラジド)処理により作用させ、フラボン前駆体である β- ジケトン(10)を得る。
フラボンのA環部に対応する出発物質であるアセトフェノン誘導体(8):
出発物質である1,2,3,5-テトラメトキシベンゼンは市販されている。まず、1,2,3,5-テトラメトキシベンゼンに対して、フリーデル・クラフツ反応により(3)を生成する。フリーデル・クラフツ反応は、非プロトン性溶媒中で、塩化アルミニウム等のルイス酸の存在下で塩化アセチルと反応させることにより行うことができる。塩基性条件下でヨウ化メチルと反応させることにより(3)をメチル化して、1-(2,3,4,6-テトラメトキシフェニル)エタノン(4)を生成する。次に、SeO2触媒の存在下で過酸化水素を作用させて、バイヤー・ビリガー反応により(4)のケトンをエステル化して(5)を生成し、過溶媒分解により2,3,4,6-テトラメトキシフェノール (6) を得ることができる。 The starting material 1,2,3,5-tetramethoxybenzene is commercially available. First, (3) is produced by Friedel-Crafts reaction with 1,2,3,5-tetramethoxybenzene. The Friedel-Crafts reaction can be carried out by reacting with acetyl chloride in the presence of a Lewis acid such as aluminum chloride in an aprotic solvent. Methylation of (3) by reaction with methyl iodide under basic conditions produces 1- (2,3,4,6-tetramethoxyphenyl) ethanone (4). Next, hydrogen peroxide is allowed to act in the presence of a SeO 2 catalyst, and the ketone of (4) is esterified by the Bayer-Billiger reaction to produce (5), and 2,3,4,6 by persolvolysis. -Tetramethoxyphenol (6) can be obtained.
次に、2,3,4,6-テトラメトキシフェノール (6) の4位の水酸基にメチル基を導入してペンタメトキシフェノール(7)とする。メチル化は、塩基性条件下でヨウ化メチルと反応させることにより行う。
次に、(7)の化合物をアシル化して、フラボンのA環部に対応するアセトフェノン誘導体(8)を得る。アシル化は、フリーデル・クラフツ反応により第1工程と同様にして行うことができる。
また、本発明の方法においてフラボンB環部に相当する出発物質である、ジメトキシ安息香酸誘導体(9'):
本発明の方法の第2工程においては、第1工程で得られたβ- ジケトンを環化させることにより、目的とするノビレチン(1)を得る。環化は、メタノール中TFAによる酸処理により行う。
本発明の方法の任意の工程である第3工程においては、ノビレチン(1)をAlCl3およびエタンチオールと反応させることにより、A環の5位が脱メチル化された誘導体を製造する。
以上の工程により、下記のノビレチンおよびその誘導体を合成することができる。
本発明の別の態様においては、ノビレチンの選択的標識化の方法が提供される。
この方法では、上述の第3工程と同様にして、ノビレチンをAlCl3およびエタンチオールで処理することにより選択的に5位を脱メチル化し、次に、DMF 中、塩基の存在下で11Cまたは14C で標識化したヨウ化メチルを用いて加熱することで、容易に5 位のメチル基が標識されたノビレチン(1*)を得ることができる。このようにして標識したノビレチンは、PET測定やトレース実験に有用である。 In this method, similar to the third step described above, nobiletin is selectively demethylated by treating it with AlCl 3 and ethanethiol, then 11 C or D 11 in DMF in the presence of a base. By heating with methyl iodide labeled with 14 C, nobiletin (1 *) labeled with the methyl group at the 5-position can be easily obtained. Nobiletin labeled in this way is useful for PET measurements and trace experiments.
本発明の方法は、精製にカラムクロマトグラフィーを必要としないため、スケールアップが容易である。さらに、本発明の方法と既知の有機合成法を適宜組み合わせて、A環のメトキシ基やB環のトリアゾールユニットを変えることにより、ノビレチンの各種の誘導体の合成ならびにその位置選択的標識化が可能である。今後、ノビレチンの更なる誘導体化、例えばビオチンタグ化、蛍光プローブの導入等により、その生理作用機序の解明に大きく寄与できるものと考えられる。 Since the method of the present invention does not require column chromatography for purification, it can be easily scaled up. Furthermore, various combinations of nobiletin and regioselective labeling are possible by appropriately combining the method of the present invention and known organic synthesis methods and changing the A ring methoxy group and the B ring triazole unit. is there. In the future, it is considered that further derivatization of nobiletin, for example, biotin tagging, introduction of a fluorescent probe, etc. can greatly contribute to elucidation of the physiological action mechanism.
以下に実施例により本発明をより詳細に説明するが、本発明はこれらの実施例により限定されるものではない。 EXAMPLES The present invention will be described below in more detail with reference to examples, but the present invention is not limited to these examples.
実施例1:1-(2-ヒドロキシ-3,4,6-トリメトキシフェニル)エタノン(3)の合成
1H NMR (500 MHz, CDCl3): d 13.8 (s, 1H, OH), 5.97 (s 1H, Ar), 3.94 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 2.62 (s, 3H, CH3).
Example 1: Synthesis of 1- (2-hydroxy-3,4,6-trimethoxyphenyl) ethanone (3)
1H NMR (500 MHz, CDCl3): d 13.8 (s, 1H, OH), 5.97 (s 1H, Ar), 3.94 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 3.82 (s, 3H , OCH3), 2.62 (s, 3H, CH3).
実施例2:1-(2,3,4,6-テトラメトキシフェニル) エタノン(4)の合成
1H NMR (500 MHz, CDCl3): d 6.26 (s, 1H, Ar), 3.89 (s, 6H, OCH3), 3.81 (s, 3H, OCH3), 3.80 (s, 3H, OCH3), 2.48 (s, 3H, CH3).
Example 2: Synthesis of 1- (2,3,4,6-tetramethoxyphenyl) ethanone (4)
1H NMR (500 MHz, CDCl3): d 6.26 (s, 1H, Ar), 3.89 (s, 6H, OCH3), 3.81 (s, 3H, OCH3), 3.80 (s, 3H, OCH3), 2.48 (s, 3H, CH3).
実施例3:2,3,4,6- テトラメトキシフェノール(6)の合成
2,3,4,6-テトラメトキシフェニルアセテート(5)のメタノール溶液にアルゴン雰囲気、室温下炭酸カリウムを加え撹拌した。TLC にて反応の完結を確認した後、反応液を 0 ℃に氷零し 6N 塩酸にて反応液が pH 1 になるまで加え反応を停止した。 続いてジエチルエーテル 200 mL を加え、抽出を 5 回行った後に無水硫酸ナトリウムにて乾燥した。ろ過後、ろ液を減圧濃縮し 2,3,4,6- テトラメトキシフェノール(6)を白色針状結晶として得た。
1H NMR (500 MHz, CDCl3): d 6.33 (s, 1H, Ar), 5.23 (s, 1H, OH), 3.96 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 3.83 (s, 3H, OCH3).
Example 3: Synthesis of 2,3,4,6-tetramethoxyphenol (6)
To a methanol solution of 2,3,4,6-tetramethoxyphenyl acetate (5), potassium carbonate was added and stirred at room temperature under an argon atmosphere. After confirming the completion of the reaction by TLC, the reaction solution was cooled to 0 ° C. with ice, and the reaction solution was added with 6N hydrochloric acid until the reaction solution reached pH 1 to stop the reaction. Subsequently, 200 mL of diethyl ether was added and extraction was performed 5 times, followed by drying over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure to obtain 2,3,4,6-tetramethoxyphenol (6) as white needle crystals.
1H NMR (500 MHz, CDCl3): d 6.33 (s, 1H, Ar), 5.23 (s, 1H, OH), 3.96 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 3.83 (s, 3H, OCH3).
実施例4:ペンタメトキシベンゼン(7)の合成
1H NMR (270 MHz, CDCl3): d 6.30 (s, 1H, Ar), 3.95 (s, 3H, OCH3), 3.85 (s, 6H, OCH3), 3.83 (s, 6H, OCH3); 13C NMR (67.8 MHz, CDCl3): d 149.1, 147.8, 136.8, 93.8, 61.4, 61.3, 56.4; MS (FAB) m/z calcd for C11H17O5+ (M+H) + 228, 実測値 228.
Example 4: Synthesis of pentamethoxybenzene (7)
1H NMR (270 MHz, CDCl3): d 6.30 (s, 1H, Ar), 3.95 (s, 3H, OCH3), 3.85 (s, 6H, OCH3), 3.83 (s, 6H, OCH3); 13C NMR (67.8 (MHz, CDCl3): d 149.1, 147.8, 136.8, 93.8, 61.4, 61.3, 56.4; MS (FAB) m / z calcd for C11H17O5 + (M + H) + 228, measured 228.
実施例5:1-(2-ヒドロキシ-3,4,5,6-テトラメトキシフェニル)エタノン(8)の合成
回収した原料を再び乾燥塩化メチレン 10 mL に溶解し、 氷零下、塩化アセチル 485μL, 6.2 mmol を加え、続いて塩化アルミニウム 560 mg, 6.6 mmol を加え、溶液を室温で 4 時間撹拌した。氷零後、反応液にジエチルエーテルを加え、次いで pH 11 になるまで 2N 水酸化ナトリウム水溶液を加えた。 有機層をとり、無水硫酸マグネシウムを加え乾燥した。ろ過後、ろ液を減圧濃縮し、原料のペンタメトキシベンゼン (513 mg, 回収率51%) を回収した。また、水層をとり、ジエチルエーテルで洗浄後、氷零下、pH 1になるまで 6N 塩酸を加えた。水溶液をジエチルエーテルで 3 回抽出し、有機層をとり、無水硫酸マグネシウムを加え乾燥した。ろ過後、ろ液を減圧濃縮し、残渣をフラッシュシリカゲルカラムクロマトグラフィー(展開溶媒ヘキサン:酢酸エチル = 4:1 → 2:1) にて精製し、1-(2-ヒドロキシ-3,4,5,6-テトラメトキシフェニル)エタノン (508 mg, 収率 45%) を黄色油状物質として得た。それらを合わせ、1-(2-ヒドロキシ-3,4,5,6-テトラメトキシフェニル)エタノン(8) (1.0 g, 収率 60%) と、 原料のペンタメトキシベンゼン (513 mg, 回収率 34%) を得た。
1H NMR (500 MHz, CDCl3): d 13.2 (s, 1H, OH), 4.08 (s, 3H, OCH3), 3.95 (s, 3H, OCH3) , 3.90 (s, 3H, OCH3), 3.95 (s, 3H, OCH3) (s, 3H, OCH3).
Example 5: Synthesis of 1- (2-hydroxy-3,4,5,6-tetramethoxyphenyl) ethanone (8)
The recovered raw material was dissolved again in 10 mL of dry methylene chloride, and acetyl chloride (485 μL, 6.2 mmol) was added under ice zero, followed by the addition of aluminum chloride (560 mg, 6.6 mmol), and the solution was stirred at room temperature for 4 hours. After zero ice, diethyl ether was added to the reaction solution, and then 2N aqueous sodium hydroxide solution was added until pH 11 was reached. The organic layer was taken and dried over anhydrous magnesium sulfate. After filtration, the filtrate was concentrated under reduced pressure to recover the raw material pentamethoxybenzene (513 mg, 51% recovery). The aqueous layer was taken, washed with diethyl ether, and 6N hydrochloric acid was added until the pH reached 1 under zero ice. The aqueous solution was extracted 3 times with diethyl ether, the organic layer was taken, dried over anhydrous magnesium sulfate. After filtration, the filtrate was concentrated under reduced pressure, and the residue was purified by flash silica gel column chromatography (developing solvent hexane: ethyl acetate = 4: 1 → 2: 1) to give 1- (2-hydroxy-3,4,5 , 6-Tetramethoxyphenyl) ethanone (508 mg, 45% yield) was obtained as a yellow oil. Combining them, 1- (2-hydroxy-3,4,5,6-tetramethoxyphenyl) ethanone (8) (1.0 g, 60% yield) and the raw material pentamethoxybenzene (513 mg, yield 34) %).
1H NMR (500 MHz, CDCl3): d 13.2 (s, 1H, OH), 4.08 (s, 3H, OCH3), 3.95 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 3.95 (s, 3H, OCH3) (s, 3H, OCH3).
実施例6:(1H-ベンゾ [d][1,2,3]トリアゾ-1-イル)(3,4-ジメトキシフェニル)メタノン(9")の合成
1H NMR (500 MHz, CDCl3): d 8.37 (d, J = 8.5 Hz, 1H, Ar), 8.05(d, J = 8.5, 1H, Ar), 7.82 (s, 1H, Ar), 7.70 (t, J = 7.5 Hz, 1H, Ar), 7.55 (t, J = 7.5 Hz, 1H, Ar), 7.04 (d, J = 7.5 Hz, 1H, Ar), 4.01 (s, 3H, OCH3), 4.00 (s, 3H, OCH3); 13C NMR (125 MHz, CDCl3): d 165.5, 153.9, 148.7, 145.5, 132.5, 130.2, 127.2, 126.1, 123.3, 120.0, 114.8, 113.9, 110.2, 56.1, 56.0; MS (FAB) m/z calcd for C15H14N3O3+ (M+H) + 283, 実測値 283.
Example 6: Synthesis of (1H-benzo [d] [1,2,3] triazo-1-yl) (3,4-dimethoxyphenyl) methanone (9 ")
1H NMR (500 MHz, CDCl3): d 8.37 (d, J = 8.5 Hz, 1H, Ar), 8.05 (d, J = 8.5, 1H, Ar), 7.82 (s, 1H, Ar), 7.70 (t, J = 7.5 Hz, 1H, Ar), 7.55 (t, J = 7.5 Hz, 1H, Ar), 7.04 (d, J = 7.5 Hz, 1H, Ar), 4.01 (s, 3H, OCH3), 4.00 (s , 3H, OCH3); 13C NMR (125 MHz, CDCl3): d 165.5, 153.9, 148.7, 145.5, 132.5, 130.2, 127.2, 126.1, 123.3, 120.0, 114.8, 113.9, 110.2, 56.1, 56.0; MS (FAB) m / z calcd for C15H14N3O3 + (M + H) + 283, measured value 283.
実施例7:ノビレチン(1)の合成
1H NMR (500 MHz, CDCl3): d 7.57 (d, J1 = 8.6 Hz, J2 = 2.1 Hz, 1H, Ar), 7.42 (d, J = 2.1, 1H, Ar), 7.00 (d, J = 8.6 Hz, 1H, Ar), 6.62 (d, 1H, CH), 4.11 (s, 3H, OCH3), 4.03 (s, 3H, OCH3), 4.00-3.95 (m, 12H, OCH3).
Example 7: Synthesis of nobiletin (1)
1H NMR (500 MHz, CDCl3): d 7.57 (d, J1 = 8.6 Hz, J2 = 2.1 Hz, 1H, Ar), 7.42 (d, J = 2.1, 1H, Ar), 7.00 (d, J = 8.6 Hz , 1H, Ar), 6.62 (d, 1H, CH), 4.11 (s, 3H, OCH3), 4.03 (s, 3H, OCH3), 4.00-3.95 (m, 12H, OCH3).
実施例8:ノビレチンの位置特異的標識化
次に、自動合成装置を用い、5-デメチルノビレチンを DMFに溶解させ、10% 水酸化テトラブチルアンモニウム水溶液を加えた。[11C]標識MeIを加え、封管して、1分間加熱した後冷却した。溶液の色は濃黄色から淡黄色に変化した。反応液をHPLCにて精製し、放射活性をもつ、[11C]標識ノビレチン (RT: 11 min) を得た。
Example 8: Position specific labeling of nobiletin
Next, using an automatic synthesizer, 5-demethylnobiletin was dissolved in DMF, and 10% tetrabutylammonium hydroxide aqueous solution was added. [11C] -labeled MeI was added, sealed, heated for 1 minute and then cooled. The color of the solution changed from dark yellow to light yellow. The reaction solution was purified by HPLC to obtain [11C] -labeled nobiletin (RT: 11 min) having radioactivity.
Claims (1)
で表される化合物を合成する方法であって、
(a)式(II):
で表される化合物とを反応させて、式(IV):
(b)式(IV)の化合物を環化させて、式(V):
(c)任意に、式(V)の化合物をAlCl3およびエタンチオールと反応させて、式(VI):
の各工程を含む方法。 Formula (I):
A method for synthesizing a compound represented by:
(A) Formula (II):
Is reacted with a compound represented by formula (IV):
(B) cyclizing the compound of formula (IV) to form formula (V):
(C) Optionally reacting the compound of formula (V) with AlCl 3 and ethanethiol to give formula (VI):
The method including each process of these.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009275181A JP4559531B1 (en) | 2009-12-03 | 2009-12-03 | Method for producing nobiletin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009275181A JP4559531B1 (en) | 2009-12-03 | 2009-12-03 | Method for producing nobiletin |
Publications (2)
Publication Number | Publication Date |
---|---|
JP4559531B1 true JP4559531B1 (en) | 2010-10-06 |
JP2011116696A JP2011116696A (en) | 2011-06-16 |
Family
ID=43048756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009275181A Active JP4559531B1 (en) | 2009-12-03 | 2009-12-03 | Method for producing nobiletin |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4559531B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103272032A (en) * | 2013-03-29 | 2013-09-04 | 阚兆云 | Natural traditional Chinese medicine composition |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3306317A1 (en) * | 2016-10-04 | 2018-04-11 | Université de Bordeaux | Novel real-time multiplexed, multi-color bioluminescence resonance energy transfer assay, apparatus, and uses thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10114766A (en) * | 1996-09-27 | 1998-05-06 | Adir | New flavone compound, its production and pharmaceutical composition comprising the same |
JP2001514156A (en) * | 1997-08-28 | 2001-09-11 | メディケム リサーチ インコーポレイテッド | Robusta flavone, intermediates, analogs and methods for their preparation |
JP2003192588A (en) * | 2001-12-27 | 2003-07-09 | National Agricultural Research Organization | Uv-induced prostaglandin e2 production suppressing agent |
JP2009155294A (en) * | 2007-12-27 | 2009-07-16 | Yuzo Tsuchida | Method for producing tricine |
JP2010053067A (en) * | 2008-08-28 | 2010-03-11 | Shizuokaken Koritsu Daigaku Hojin | Method of producing flavone derivative, and inhibitory agent for sialic-acid transferase |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3715779A1 (en) * | 1987-05-12 | 1988-11-24 | Kali Chemie Pharma Gmbh | FLAVON-3-CARBONIC ACID COMPOUNDS AND METHOD, INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
CN104306367A (en) * | 2004-11-08 | 2015-01-28 | 爱科来株式会社 | Peroxisome proliferator-activated receptor (PPAR) activator and use thereof |
WO2007083263A1 (en) * | 2006-01-23 | 2007-07-26 | Firmenich Sa | Process to prepare flavones |
-
2009
- 2009-12-03 JP JP2009275181A patent/JP4559531B1/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10114766A (en) * | 1996-09-27 | 1998-05-06 | Adir | New flavone compound, its production and pharmaceutical composition comprising the same |
JP2001514156A (en) * | 1997-08-28 | 2001-09-11 | メディケム リサーチ インコーポレイテッド | Robusta flavone, intermediates, analogs and methods for their preparation |
JP2003192588A (en) * | 2001-12-27 | 2003-07-09 | National Agricultural Research Organization | Uv-induced prostaglandin e2 production suppressing agent |
JP2009155294A (en) * | 2007-12-27 | 2009-07-16 | Yuzo Tsuchida | Method for producing tricine |
JP2010053067A (en) * | 2008-08-28 | 2010-03-11 | Shizuokaken Koritsu Daigaku Hojin | Method of producing flavone derivative, and inhibitory agent for sialic-acid transferase |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103272032A (en) * | 2013-03-29 | 2013-09-04 | 阚兆云 | Natural traditional Chinese medicine composition |
Also Published As
Publication number | Publication date |
---|---|
JP2011116696A (en) | 2011-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7906660B2 (en) | Production of isoflavone derivatives | |
BRPI0719264A2 (en) | NEBIVOLOL PREPARATION PROCESS | |
JP2012516886A (en) | Clay statin manufacturing method | |
JP4559531B1 (en) | Method for producing nobiletin | |
JPH03109384A (en) | Production of (s)-4-hydroxymethyl-gamma-lactone | |
JP6230703B2 (en) | Process for producing 4-benzyl-1-phenethyl-piperazine-2,6-dione, and its intermediate and process | |
JP6912143B2 (en) | 4-Pentafluorothiophenol compounds and preparation method and preparation method of pentafluorosulfur-substituted benzopyran compound | |
RU2709493C1 (en) | Method of producing roxadustat | |
CN110143927B (en) | Benzimidazole chalcone derivative and preparation method and application thereof | |
JP3338854B2 (en) | Method for producing new areno [e] indole | |
KR101087498B1 (en) | Binaphthol aldehyde derivatives and method for preparing the same | |
Manchand et al. | Synthesis of the leukotriene antagonist ablukast | |
SU751328A3 (en) | Method of preparing hellebrigenine derivatives or their salts | |
KR101558733B1 (en) | Effective synthetic method of natural product moracin N | |
CN110669031B (en) | Total synthesis method of natural product isoperidone J | |
KR101122397B1 (en) | An economical synthesis of ailanthoidol | |
CN113004245B (en) | Preparation method of desloratadine | |
KR101558742B1 (en) | New synthetic method of natural product moracin Y | |
JP2675569B2 (en) | Method for producing 2,3-dihydrobenzofuran derivative | |
Padmavathi et al. | Synthesis of methyl 2-methoxy-5-hydroxycinnamate, a metabolite of Murraya paniculata | |
JP2946423B2 (en) | Process for producing aphanorphin and intermediates thereof | |
EP3733656A1 (en) | Method for synthesis of lobaric acid and analog thereof | |
KR101558738B1 (en) | New total synthetic method of natural product moracin S | |
Du et al. | Asymmetric synthesis of methyl 6-deoxy-3-O-methyl-α-l-mannopyranoside from a non-carbohydrate precursor | |
SU726094A1 (en) | 5-hydroxybenzofuran derivatives as semi-finished products for synthesis of 2-phenyl-3-acyl-4-aminomethyl-5-oxybenzofurans and their preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A80 Effective date: 20091218 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20100409 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20100420 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100413 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100420 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20100603 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100616 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100630 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100715 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100722 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4559531 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130730 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |